Little Green Pharma is focused on the medical side of cannabis and was the first company in Australia to produce and export cannabis medicine. They were also the first company in Denmark to produce and register locally grown cannabis medicine. They have one facility in Denmark to service the Northern hemisphere and one facility in Australia to service the Southern hemisphere.
FACILITIES:
The facility in Denmark is 275,000 sq ft and the cultivation is GACP-certified and manufacturing is GMP-certified.
CLINICAL TRIALS: Yes.
OWNERSHIP:
The company has a subsidiary called Reset Mind Sciences which is focused on offering psychedelic assisted psychotherapy.
NEWS & PARTNERSHIPS:
2020
The company entered into a 3-year agreement with Demecan for the company to supply up to 1,000 KG of medicinal dried flower.
The company signed a 5-year binding purchase agreement with Astral Health, a subsidiary of Lyphe Group, to supply the company with it’s medicinal cannabis products.
The company entered into a strategic partnership with national private health insurer Health Insurance Fund of Australia which will allow for a rebate of medicinal cannabis to eligible HIF members. The partnership will also research the role medicinal cannabis can play in improving patient quality of life, with eligible HIF members entitled to priority participation in such research. The partnership will last for 18 months to 2 years, depending on how long the study takes.
2021
The company won the 2-year French government tender for the French medical cannabis trial and was appointed as a primary medicinal cannabis oil manufacturer in partnership with Intsel Chimos for 2 CBD-dominant oil medicines and a backup supplier for a balanced THC:CBD oil medicine.
The company signed a 4-year distribution agreement with Pharmareserve Hellas for the distribution of Little Green Pharma-branded oil medicines and cannabis flower in Greece. 2 years involve exclusive supply and distribution of Little Green Pharma-branded cannabis medicines in Greece and they are not allowed to promote any other cannabis medicine in Greece for at least 2 years, with further exclusivity periods to be extended by agreement. Product revenues will be shared 50/50.
The company was granted a Schedule 9 license to supply psilocybin by the Western Australia Government Department of Health which the company is planning to use for the production of psilocybin.
The company signed a 5-year exclusive distribution agreement with Medezin, a subsidiary of Pelion for the distribution of LGP’s medicinal cannabis oil and high THC flower products in Poland targeting sales of at least 20% of the Polish medicinal cannabis oil Market and at least 10% of the Polish high-THC medicinal cannabis flower Market. In 2023, the company’s Desert Flame high THC medicinal cannabis flower product was granted market authorization in Poland.
The company signed a 5-year distribution agreement with Denmark-based Balancial Danmark for the supply of medicinal cannabis oil and flower products at a fixed price while at the same time restricting Balancial from manufacturing or supplying similar medicinal cannabis oil or flower products until it has purchased a minimum of 20,000 units from LGP. Every order will be a minimum of 2,000 units and LGP is not obligated to fulfil orders received unless it has confirmed the order with 100% of the first shipment paid in advance and the following shipments require a 50% upfront payment.
2022
The company signed a 3-year offtake agreement with Demecan involving 3 high-THC strains for distribution in Germany. For Demecan to maintain strain exclusivity and following a ramp-up period of between 6 and 12 months, Demecan is required to purchase at least 450 KG per annum of each strain. Under the agreement, Demecan pays 50% of the development costs of each strain successfully developed and Little Green Pharma has the right to terminate the agreement should its cost of production exceed the product purchase price.
The company was awarded a tender for EU-GMP medicinal cannabis flower with the Italian government imported from its Danish facility.
The company won the National Export Awards for International Health.
The company signed a 2-year supply agreement with Ilios Santé for the supply of a non-exclusive LGP high-THC white label medicinal cannabis product into the German market. The company has the option to terminate the agreement should the cost of production exceed the minimum product purchase price.
The company signed a 2-year exclusive supply agreement with Cannamedical for the supply of a high-THC strain medicinal cannabis in bulk to the German market. Cannamedical needs to order a specified minimum quantity every 6 months to able to keep its exclusivity of the strain. For every percentage point that the THC is higher or lower than 22%, ther will be an adjustment in price. Shipments are under FCA INCO terms from LGP’s Danish facility, Cannamedical will arrange for shipping and release in Germany. In late 2022, the company signed its second 2-year exclusive supply agreement with Cannamedical for another cannabis cultivar, namely the SMS strain with the same conditions as the first agreement.
The company signed a 3-year supply agreement starting with first shipment with a minimum purchase order of between 10 to 20 KG post ramp-up for flower products and 500 oil units with every shipment. The agreement was made with Sana Life Sciences for the distribution of Little Green Pharma-branded oils and flower products covering the UK as well as Jersey, Guernsey and the Isle of Man. Under the agreement, the company may pass on 50% of any increases in the cost of production above 110% of its production costs at the date of the agreement. At the same time, the company is giving Sana mutual exclusivity of the company’s 10:10 Classic Oil as well as equivalent ratio oils, subject to Sana meeting certain minimum exclusivity purchase thresholds per annum.
The company signed a large volume take or pay contract with Four 20 Pharma for the exclusive supply of a high-THC strain into Germany over 30 months.
The company signed a 3-year distribution agreement with AMP covering Little Green Pharma-branded cannabis oil medicines in Germany with a promise to not promote any other cannabis oils in Germany. The company gave AMP the exclusive rights to 2 oils and 3 oils are distributed on a non-exclusive basis.
The company ended its exclusive supply agreement with Four 20 Pharma as certain conditions of the agreement was not fulfilled.
2023
The company was appointed to be a primary CBD oil manufacturer for 1 more year under the French medical cannabis trial.
As France integrates medicinal cannabis into its healthcare system, the company and 2 others were given the exclusive right to supply patients with medicinal cannabis.
The company launched the Cherry Co brand.
2024
The company received a 5million AUD R&D rebate.
The company launched Indicare with THC 22 Sativa and THC 20 Indica product lines, made available through the Special Access Scheme.
2025
The company acquired its distribution partner Health House.
2026
The company announced a binding merger with Cannatrek in a transformational deal that creates a vertically integrated medicinal cannabis group with combined scale across manufacturing, distribution & clinics.
BRANDS:
Lush Labs collaborates with JR Strain, a legacy grower with over 36 years of experience as well as his own genetic library. The brand also uses the latest advancements from the lab and aeroponic cultivation to advance their products. All products have been cold-cured for at least 3 weeks and are hand-trimmed and slow-dried.
CherryCo offers smaller flower products at more affordable price called Little Buddies in 15-gram bags.